Payment overview · 2025
General Payments
$54.64
3 reported records · 3 companies
Healthcare provider profile · identity verified
Syed Hasan Raza, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MEDINA, NY · NPI 1497715296
Verified facts
What the public records show
CMS Open Payments records show Syed Hasan Raza, MD received $54.64 in general payments during 2025 across 3 reported records.
Verona Pharma, Inc. accounted for 39.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $21.29 | 39.0% | 1 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $17.64 | 32.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.71 | 28.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $54.64 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 86 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
15 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
86 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 419 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 297 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 275 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 238 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 208 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 186 | 50 |
| Atorvastatin Calcium | Atorvastatin Calcium | 172 | 51 |
| Lisinopril | Lisinopril | 154 | 43 |
| Metformin Hcl | Metformin Hcl | 152 | 36 |
| Omeprazole | Omeprazole | 144 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 141 | 21 |
| Celecoxib | Celecoxib | 135 | 26 |
| Losartan Potassium | Losartan Potassium | 134 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 129 | 26 |
| Ozempic | Semaglutide | 124 | 22 |
| Famotidine | Famotidine | 116 | 24 |
| Azithromycin | Azithromycin | 115 | 82 |
| Baclofen | Baclofen | 109 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 109 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 105 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 29 |
| Simvastatin | Simvastatin | 99 | 27 |
| Tramadol Hcl | Tramadol Hcl | 98 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 92 | 21 |
| Jardiance | Empagliflozin | 90 | 24 |
| Montelukast Sodium | Montelukast Sodium | 90 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 89 | 17 |
| Buspirone Hcl | Buspirone Hcl | 87 | 16 |
| Alprazolam | Alprazolam | 86 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 86 | 15 |
| Eliquis | Apixaban | 85 | 16 |
| Methylprednisolone | Methylprednisolone | 85 | 71 |
| Allopurinol | Allopurinol | 81 | 16 |
| Furosemide | Furosemide | 78 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 18 |
| Trazodone Hcl | Trazodone Hcl | 74 | 17 |
| Farxiga | Dapagliflozin Propanediol | 71 | 21 |
| Glimepiride | Glimepiride | 71 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 66 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 65 | 14 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 64 | suppressed |
| Pregabalin | Pregabalin | 63 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 62 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 61 | 38 |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | suppressed |
| Clonazepam | Clonazepam | 56 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 54 | 18 |
| Meloxicam | Meloxicam | 54 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 54 | 13 |
| Topiramate | Topiramate | 50 | suppressed |
| Carvedilol | Carvedilol | 49 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 49 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 44 | 12 |
| Cephalexin | Cephalexin | 43 | 32 |
| Prednisone | Prednisone | 43 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | suppressed |
| Ezetimibe | Ezetimibe | 38 | suppressed |
| Atenolol | Atenolol | 37 | suppressed |
| Nystatin | Nystatin | 37 | 21 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 36 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 20 |
| Arnuity Ellipta | Fluticasone Furoate | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Potassium Chloride | Potassium Chloride | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 30 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 20 |
| Ondansetron Odt | Ondansetron | 30 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Loperamide | Loperamide Hcl | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 19 |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 13 |
| Digoxin | Digoxin | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 11 |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $54.64 · 3 records | Verona Pharma, Inc. | BRAFTOVI, Ohtuvayre, TRELEGY ELLIPTA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error